AVIEW LCS vs ClearRead CT

Direct competitors — feature-level head-to-head below. Comparability 92/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AVIEW LCS

by Coreline Soft Co.

ClearRead CT

by RIVERAIN TECHNOLOGIES

AI Verdict

Both AVIEW LCS and ClearRead CT are highly comparable AI-powered solutions for cardiothoracic health, focusing on pulmonary nodule detection and coronary artery calcification analysis from CT scans. While AVIEW LCS offers specific features for COPD assessment and Lung-RADS classification, ClearRead CT distinguishes itself with patented vessel suppression technology and quantified improvements in reading time and detection accuracy. Both aim to enhance diagnostic accuracy and streamline radiology workflows.

Choose AVIEW LCS if…

Choose AVIEW LCS if your institution requires a comprehensive, integrated AI solution for multi-disease assessment from a single low-dose CT scan, encompassing lung cancer, COPD, and coronary artery calcification. This tool is particularly well-suited for screening programs that benefit from fully automatic analysis, detailed emphysema quantification, and streamlined reporting with automated nodule comparisons over time.

View AVIEW LCS →

Choose ClearRead CT if…

Choose ClearRead CT if your priority is to significantly improve the accuracy and efficiency of pulmonary nodule detection, especially in challenging cases where patented vessel suppression technology can enhance visibility. This tool is ideal for radiology departments aiming to reduce reading times and minimize missed actionable nodules through advanced AI and automated nodule tracking across prior exams.

View ClearRead CT →

For a physician evaluating AI tools for cardiothoracic imaging, AVIEW LCS and ClearRead CT offer distinct strengths. AVIEW LCS provides a comprehensive, integrated analysis from a single low-dose CT scan, covering lung cancer screening, COPD, and coronary artery calcification. Its key features include automated lung nodule detection and analysis with Lung-RADS classification, emphysema quantification, and detailed coronary artery calcification scoring. This makes AVIEW LCS particularly well-suited for practices seeking a holistic cardiopulmonary assessment solution that streamlines multiple diagnostic pathways into one platform.

ClearRead CT, on the other hand, excels in enhancing pulmonary nodule detection through its patented vessel suppression technology, aiming to improve diagnostic accuracy and reduce reading times. While it also offers coronary artery calcification scoring, its primary focus appears to be on refining nodule detection and characterization, including solid, part-solid, and ground glass nodules. Physicians prioritizing advanced nodule detection capabilities and a significant reduction in reading time, especially in high-volume settings, might find ClearRead CT to be the more advantageous choice. The practical difference lies in AVIEW LCS’s broader, integrated cardiopulmonary assessment versus ClearRead CT’s specialized focus on optimizing nodule detection with unique vessel suppression.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AVIEW LCS	ClearRead CT
Pricing	Contact for pricing	Contact for pricing
Deployment	Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)	On-premise (stand-alone server, virtual machine) and Cloud
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ClearRead CT

ClearRead CT (Tool B) explicitly highlights a 'Reduced Reading Time (up to 36%)', which is a direct and quantifiable benefit for the end-user, enhancing workflow efficiency. While AVIEW LCS (Tool A) offers automated reporting, the specific claim of reduced reading time makes Tool B's usability impact more pronounced for radiologists.

Clinical Value

AVIEW LCS

AVIEW LCS (Tool A) provides a more comprehensive clinical assessment by integrating fully automatic analysis of lung cancer, COPD, and coronary artery calcification from a single low-dose CT scan. This broader scope, including Lung-RADS classification and emphysema quantification, offers a wider range of diagnostic insights compared to ClearRead CT's (Tool B) primary focus on nodule detection and CAC scoring.

Pricing & Value

Tie

Both AVIEW LCS (Tool A) and ClearRead CT (Tool B) require direct contact with the vendor for pricing information. Without any transparent pricing details, comparative cost structures, or specific return on investment data for either solution, it is not possible to determine which offers superior pricing or overall value.

Enterprise Readiness

AVIEW LCS

AVIEW LCS (Tool A) explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA), providing clear assurance for enterprise deployment. Furthermore, Tool A offers a broader range of deployment options, including Cloud-based, Hybrid, Locally on dedicated hardware, and Locally virtualized, offering greater flexibility for diverse IT environments compared to Tool B's stated options.

Innovation

ClearRead CT

While both tools leverage AI, ClearRead CT (Tool B) features 'Patented Vessel Suppression (Clear Visual Intelligence)' as a distinct technological innovation. This unique approach aims to enhance the clarity and accuracy of pulmonary nodule detection by minimizing obscuring vessels, which appears to be a specific and impactful advancement in image processing.

Support & Docs

Tie

Neither the provided structured facts nor general web searches yielded specific, publicly available information regarding the level of customer support, service agreements, or documentation portals for either AVIEW LCS (Tool A) or ClearRead CT (Tool B). Without comparative details, it is not possible to distinguish between the two on this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AVIEW LCS	ClearRead CT
Name	AVIEW LCS	ClearRead CT
Company	Coreline Soft Co.	RIVERAIN TECHNOLOGIES
Tagline	AI-Powered Lung Cancer Screening & Cardiopulmonary Assessment	AI-Driven Clarity for Faster & More Confident Nodule Detection
Key Features (Nodule Analysis)	Automated lung nodule detection and analysis, Lung-RADS classification and reporting, Nodule volume quantification and 3D segmentation, Automated comparison of nodules in follow-up CT scans	Pulmonary Nodule Detection (solid, part-solid, ground glass), Nodule Characterization and Measurement (volume, diameter, location, type, depth), Automated Nodule Tracking and Comparison to Prior Exams
Key Features (Cardiovascular Analysis)	Coronary Artery Calcification (CAC) scoring (Agatston, volume, mass)	Coronary Artery Calcification (CAC) Scoring (ungated, non-contrast CTs)
Key Features (Workflow/Integration)	Comprehensive, automated report generation, Integration with PACS/RIS and third-party platforms	Reduced Reading Time (up to 36%), Seamless PACS Integration / Vendor-neutral processing